Q-omics provides the consensus-scored GAPDHP20 profile across patient tissues and cancer cell-line models. GAPDHP20 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, GAPDHP20 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, GAPDHP20 RNA expression shows 8,039 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, KIRC, and GBM as cancer lineages where GAPDHP20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP20 survival associations across molecular data types. GAPDHP20 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP20 RNA expression–survival associations across cancer types. High GAPDHP20 expression shows unfavorable associations in UCS, LUAD, THCA and HNSC, but favorable associations in UCEC and BRCA. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for GAPDHP20 RNA expression.
This table summarizes GAPDHP20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP20 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, LIHC, LUAD and BLCA. The KIRC box plot shows higher GAPDHP20 RNA expression in tumor versus normal tissue (log2 FC = +0.044, t-test p = .002).
This table shows molecular features associated with GAPDHP20 in patient tissues and cancer cell lines. In patient samples, GAPDHP20 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
